Evidence map›Paper›PMID 28730299›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2017

Prophylactic etanercept treatment in cisplatin ototoxicity.

Sinem Dasli, Murat Topdag, Ahmet Mutlu, Ahmet Kara, Murat Ozturk

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Sinem DasliDerince Education and Research Hospital, ENT Clinic, 41100, Derince, Kocaeli, Turkey. yagmur_sd@hotmail.com.ORCID http://orcid.org/0000-0002-9129-1653
Murat TopdagAltunizade Acibadem Hospital ENT Clinic, 34662, Istanbul, Turkey.
Ahmet MutluUskudar State Hospital, Istanbul, Turkey.
Ahmet KaraDepartment of Otolaryngology, Sakarya University Faculty of Medicine, 54000, Sakarya, Turkey.
Murat OzturkDepartment of Otolaryngology, Kocaeli University Faculty of Medicine, 41380, Kocaeli, Turkey.
Kocaeli Üniversitesi · TRAcıbadem University · TRSakarya University · TRÜsküdar University · TR

Funding

Kocaeli Üniversitesi 2014143HDP
6 · The paper itself

Abstract

The aim of our study was to evaluate the audiological protective effects of etanercept using distortion product otoacoustic emission (DPOAE) in rats with hearing loss due to cisplatin ototoxicity. The study began with 36 healthy female albino rats; 31 rats had good measurements in DPOAE and were included in the study. On day 0, a single dose of etanercept was given by intraperitoneal administration to 15 rats (etanercept group). No medication was given to the control group. After 24 h, 16 mg/kg cisplatin was given to all rats. DPOAE measurements were performed on the 3rd, 7th, and 21st day. After the DPOAE test on the 21st day, the animals were killed by decapitation. Between-group and intra-group comparisons were made using the data of the two groups. A statistically significant difference was observed on the 3rd day at 4921 Hz and higher frequencies, on the 7th day at 6064 Hz and higher frequencies, and on the 21st day at 6494 Hz and higher frequencies (p < 0.05). We observed 10% ototoxicity in the etanercept group and 56% ototoxicity in the control group. A single dose of etanercept 1 day before cisplatin administration decreases cisplatin ototoxicity in the early period. This effect comes to the fore especially over 4500 Hz frequencies at 65 dB and higher.

Indexed as

Hearing LossAnimalsAntineoplastic AgentsCisplatinEtanerceptOtoacoustic Emissions, SpontaneousProtective AgentsRatsTreatment OutcomeAntineoplastic AgentsCisplatinEtanerceptProtective AgentsCisplatinEtanerceptOtoacoustic emissionsOtotoxicity

Identifiers

PMID28730299
OpenAlexW2737068784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.